Phaseline

Companies › Neela Therapeutics

Neela Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Sep 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CLN-301
Intrathecal AAV9 gene therapy for CLN3 replacement
CLN3Phase 1CLN3Sep 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03770572CLN-301Phase 1CLN3Metabolic and endocrineSep 2029

Targets

CLN3 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.